MARKET

SLNO

SLNO

Soleno Therapeutics Inc
NASDAQ
46.16
+0.50
+1.10%
Closed 16:02 05/17 EDT
OPEN
45.42
PREV CLOSE
45.66
HIGH
46.82
LOW
44.53
VOLUME
334.44K
TURNOVER
0
52 WEEK HIGH
53.82
52 WEEK LOW
3.690
MARKET CAP
1.68B
P/E (TTM)
-17.2245
1D
5D
1M
3M
1Y
5Y
Soleno Therapeutics Stands with the Prader-Willi Syndrome Community
Soleno Therapeutics launches a groundbreaking initiative in honor of Prader-Willi Syndrome (PWS) Awareness Day. The campaign aims to raise awareness of PWS and celebrate individuals living with this life-threatening disease. Soleno is a clinical-stage biopharmaceutical company developing novel therapies for rare diseases.
Barchart · 5d ago
Soleno Therapeutics Is Maintained at Outperform by Oppenheimer
Dow Jones · 05/13 12:46
Soleno Therapeutics Price Target Cut to $59.00/Share From $65.00 by Oppenheimer
Dow Jones · 05/13 12:46
Oppenheimer Maintains Outperform on Soleno Therapeutics, Lowers Price Target to $59
Benzinga · 05/13 12:36
SOLENO THERAPEUTICS <SLNO.O>: OPPENHEIMER CUTS TARGET PRICE TO $59 FROM $65
Reuters · 05/13 12:16
Weekly Report: what happened at SLNO last week (0506-0510)?
Weekly Report · 05/13 09:51
Soleno Therapeutics (SLNO) Receives a Buy from Stifel Nicolaus
TipRanks · 05/13 02:06
Baird Initiates Coverage of Soleno Therapeutics (SLNO) with Outperform Recommendation
NASDAQ · 05/11 04:02
More
About SLNO
Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate, Diazoxide Choline Extended-Release tablets (DCCR), extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), recently completed its Phase 3 development program. DCCR is a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. DCCR’s mode of action with targets in the brain, pancreas and fat tissue has the potential to impact complex diseases like PWS to reduce appetite, reduce food seeking, improve satiety, improve insulin and leptin resistance and reduce body fat. The Company has a Fast-Track designation for DCCR in PWS and an orphan designation for the drug in the United States and the European Union.

Webull offers Soleno Therapeutics Inc stock information, including NASDAQ: SLNO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLNO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLNO stock methods without spending real money on the virtual paper trading platform.